RESULTS ( 1 ) EQ-5D was valid and responsive for skin conditions and most cancers ; in vision , its performance varied according to aetiology ; and performance was poor for hearing impairments .
The HUI3 performed well for hearing and vision disorders .
It also performed well in cancers although evidence was limited and there was no evidence in skin conditions .
Response mapping using all the domain scores was the best performing model for the EORTC QLQ-C30 .
In an exploratory analysis , a limited dependent variable mixture model performed better than an equivalent linear model .
3 ) The exploratory valuation study found that bolt-on items for vision , hearing and tiredness had a significant impact on values of the health states , but the direction and magnitude of differences depended on the severity of the health state .
The vision bolt-on item had a statistically significant impact on EQ-5D health state values and a full valuation model was estimated .
EQ-5D performs well in studies of cancer and skin conditions .
Mapping techniques provide a solution to predict EQ-5D values where EQ-5D has not been administered .
For conditions where EQ-5D was found to be inappropriate , including some vision disorders and for hearing , bolt-ons provide a promising solution .
BACKGROUND The National Institute for Health and Care Excellence recommends the use of generic preference-based measures ( GPBMs ) of health for its Health Technology Assessment s ( HTAs ) .
However , these data may not be available or appropriate for all health conditions .
OBJECTIVES To determine whether GPBMs are appropriate for some key conditions and to explore alternative methods of utility estimation when data from GPBMs are unavailable or inappropriate .
( 2 ) Potential modelling approaches to ' map ' EQ-5D values from condition-specific and clinical measures of health [ European Organisation for Research and Treatment of Cancer Quality -of-life Question naire Core 30 ( EORTC QLQ-C30 ) and Functional Assessment of Cancer Therapy - General Scale ( FACT-G ) ] are compared for predictive ability and goodness of fit using two separate data sets . (
The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study
Background Patient-reported outcome ( PROs ) measures are being used more frequently in investigational studies of treatments for moderate to severe plaque psoriasis . The objective of this study was to examine the relationships among the Dermatology Life Quality Index ( DLQI ) , the Short Form 36 ( SF-36 ) , and the EuroQOL 5D ( EQ-5D ) and to assess their validity , responsiveness , and estimates of minimum important differences . Methods A Phase II , r and omized , double-blind , parallel group , placebo-controlled , multi-center clinical trial assessed the clinical efficacy and safety of two doses of subcutaneously administered adalimumab vs. placebo for 12 weeks in the treatment of 147 patients with moderate to severe plaque psoriasis . This study provided the opportunity to evaluate the validity and responsiveness to change in clinical status of PROs instruments . Patients completed the DLQI , SF-36 , and EQ-5D question naires at baseline and at 12 weeks . Blinded investigators assessed the Psoriasis Area and Severity Index ( PASI ) scores and the Physician 's Global Assessment ( PGA ) scores of enrolled patients . The responsiveness of the measures to changes in the clinical endpoints from baseline to Week 12 was assessed . Estimates of minimum important differences ( MID ) were derived . All analyses were performed with blinded data ; findings and conclusions were not biased based on treatment condition . Results The dermatology-specific DLQI was highly correlated to clinical endpoints at baseline and at Week 12 , and was the most responsive PRO to changes in endpoints . Compared with the SF-36 , the EQ-5D index score and VAS scores were generally more highly correlated with clinical endpoints , but displayed about the same degree of responsiveness . The most responsive SF-36 scales were the Bodily Pain and Social Functioning scales . Estimates of the MID for the DLQI ranged from 2.3–5.7 and for the SF-36 Physical Component Summary ( PCS ) score ranged from 2.5–3.9 . Conclusion This study provides support for the continued use of the DLQI and SF-36 PCS in the assessment of treatments for psoriasis . On the basis of the results from this trial , the EQ-5D should be considered as a general PRO measure in future clinical trials of patients with moderate to severe plaque psoriasis
RESULTS ( 1 ) EQ-5D was valid and responsive for skin conditions and most cancers ; in vision , its performance varied according to aetiology ; and performance was poor for hearing impairments .
The HUI3 performed well for hearing and vision disorders .
It also performed well in cancers although evidence was limited and there was no evidence in skin conditions .
Response mapping using all the domain scores was the best performing model for the EORTC QLQ-C30 .
In an exploratory analysis , a limited dependent variable mixture model performed better than an equivalent linear model .
3 ) The exploratory valuation study found that bolt-on items for vision , hearing and tiredness had a significant impact on values of the health states , but the direction and magnitude of differences depended on the severity of the health state .
The vision bolt-on item had a statistically significant impact on EQ-5D health state values and a full valuation model was estimated .
EQ-5D performs well in studies of cancer and skin conditions .
Mapping techniques provide a solution to predict EQ-5D values where EQ-5D has not been administered .
For conditions where EQ-5D was found to be inappropriate , including some vision disorders and for hearing , bolt-ons provide a promising solution .
BACKGROUND The National Institute for Health and Care Excellence recommends the use of generic preference-based measures ( GPBMs ) of health for its Health Technology Assessment s ( HTAs ) .
However , these data may not be available or appropriate for all health conditions .
OBJECTIVES To determine whether GPBMs are appropriate for some key conditions and to explore alternative methods of utility estimation when data from GPBMs are unavailable or inappropriate .
( 2 ) Potential modelling approaches to ' map ' EQ-5D values from condition-specific and clinical measures of health [ European Organisation for Research and Treatment of Cancer Quality -of-life Question naire Core 30 ( EORTC QLQ-C30 ) and Functional Assessment of Cancer Therapy - General Scale ( FACT-G ) ] are compared for predictive ability and goodness of fit using two separate data sets . (